Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Corp. stock has experienced significant volatility and a substantial decline. Key events include a significant stock price decline, rejection of capital increase proposals, approval for a Phase 2/3 clinical trial of SIL204, the release of fourth quarter and full year 2025 financial results, a board membership change, and a $6.0 million public offering in September 2025, where the company also regained compliance with Nasdaq listing requirements.

As a clinical-stage biopharmaceutical company, Silexion Therapeutics Corp. does not have commercialized products, so traditional demand seasonality is not applicable. However, there is some seasonality observed in the company's stock performance, with July showing the highest probability of positive returns and December the lowest.

Silexion Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on RNAi-based cancer drugs and delivery systems for solid tumors, operating in the Biotechnology and Pharmaceuticals & Biotech sectors. The company utilizes its proprietary LODER delivery platform. Its product pipeline includes SiG12D-LODER, which has completed preclinical studies and a Phase I clinical trial for pancreatic cancer, Prostate-LODER, currently in preclinical studies for prostate cancer, GBM-LODER, in preclinical studies for Glioblastoma Multiform, and SIL204, a second-generation product candidate designed to inhibit the KRAS oncogenic process in pancreatic cancer and is being developed as a first-line treatment for locally advanced pancreatic cancer patients in combination with standard-of-care chemotherapy.

Silexion Therapeutics Corp. is headquartered in Jerusalem, Israel. The company collaborates with Catalent in Limoges, France, for SIL204 development and clinical manufacturing. Silexion also plans regulatory submissions for its clinical trials in the European Union.

Silexion Therapeutics has maintained a positive brand reputation through advancements in its preclinical and clinical programs. Positive preclinical findings for SIL204 and regulatory milestones, such as approval for a Phase 2/3 clinical trial, contribute positively to its reputation. Collaborations with companies like Catalent further enhance its standing.

Silexion Therapeutics Corp. has both institutional and individual owners. Institutional investors own 10.95% of the stock, with major holders including Citadel Advisors Llc and UBS Group AG. Individual insider ownership is significant at 17.50%, with key owners including Ilan Levin and Moringa Sponsor LP.